SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* Flynn James E (Last) (First) (Middle) 780 THIRD AVENUE, 37TH FLOOR (Street) NEW YORK NY 10017 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol AdaptHealth Corp. [ AHCO ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner Officer (give title below) X Other (specify below) *Director by Deputization
	3. Date of Earliest Transaction (Month/Day/Year) 11/08/2019
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/08/2019		A(1)		12,400,000	A	$10	14,900,000	I	Through Deerfield Private Design Fund IV, L.P.(2)(3)
Common Stock	11/08/2019		J(4)		652,253(4)	D	$0.00(4)	2,279,888(4)	I	Through Deerfield/RAB Ventures, LLC(2)(3)
Common Stock	11/08/2019		J(5)		6,087	D	$0.00(5)	20,000	I	Through Deerfield Management Company, L.P.(2)(3)(6)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Private Placement Warrants	$11.5	11/08/2019		J(4)			460,685(4)	(7)	(7)	Common Stock	460,685(4)	$0.00(4)	1,640,981(4)	I	Through Deerfield/RAB Ventures, LLC(2)(3)
Public Warrants	$11.5							(8)	(8)	Common Stock	833,333		833,333	I	Through Deerfield Private Design Fund IV, L.P.(2)(3)

1. Name and Address of Reporting Person* Flynn James E (Last) (First) (Middle) 780 THIRD AVENUE, 37TH FLOOR (Street) NEW YORK NY 10017 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer X Director X 10% Owner Officer (give title below) X Other (specify below) *Director by Deputization

1. Name and Address of Reporting Person* Deerfield Mgmt IV, L.P. (Last) (First) (Middle) 780 THIRD AVENUE, 37TH FLOOR (Street) NEW YORK NY 10017 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer X Director X 10% Owner Officer (give title below) X Other (specify below) * Director by Deputization

1. Name and Address of Reporting Person* DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (Last) (First) (Middle) 780 THIRD AVENUE, 37TH FLOOR (Street) NEW YORK NY 10017 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer X Director X 10% Owner Officer (give title below) X Other (specify below) * Director by Deputization

1. Name and Address of Reporting Person* Deerfield Private Design Fund IV, L.P. (Last) (First) (Middle) 780 THIRD AVENUE 37TH FLOOR (Street) NEW YORK NY 10017 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer X Director X 10% Owner Officer (give title below) X Other (specify below) * Director by Deputization

Explanation of Responses:

1. On November 8, 2019, in connection with (and immediately prior to) the consummation of the Issuer's initial business combination (the "AdaptHealth Transaction") with AdaptHealth Holdings, LLC ("AdaptHealth"), Deerfield Private Design Fund IV, L.P. ("Deerfield Private Design Fund IV") acquired from the Issuer 12,400,000 shares of common stock of the Issuer.

2. This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Deerfield Private Design Fund IV is a member of Deerfield/RAB Ventures, LLC ("DRV LLC"), and is entitled to appoint one of the two members of DRV LLC's board of managers. Deerfield Mgmt IV, L.P. is the general partner of Deerfield Private Design Fund IV. Deerfield Management Company, L.P. ("Deerfield Management") is the investment manager of Deerfield Private Design Fund IV. James E. Flynn is the sole member of the general partner of each of Deerfield Management and Deerfield Mgmt IV, L.P.

3. In accordance with Instruction 4(b)(iv) to Form 4, the entire amount of the Issuer's securities held by Deerfield Private Design Fund IV or for the benefit of Deerfield Management, or in which Deerfield Private Design Fund IV has a pecuniary interest through DRV LLC, is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

4. On November 8, 2019, in connection with (and immediately prior to) the consummation of the Issuer's initial business combination, DRV LLC transferred to AdaptHealth and certain of its equityholders and employees shares of the Issuer's common stock and Private Placement Warrants, in each case, for no consideration. The numbers set forth in Column 4 of Table I and Columns 5 and 7 of Table II reflect the numbers of such transferred shares of common stock and Private Placement Warrants, as applicable, in respect of which, at the time of such transfer, Deerfield Private Design Fund IV had a pecuniary interest through its interest in DRV LLC, and the numbers set forth in Column 5 of Table I and Column 9 of Table II reflect the numbers of shares of common stock and Private Placement Warrants held by DRV LLC following such transfer in which Deerfield Private Design Fund IV had a pecuniary interest through its interest in DRV LLC.

5. On November 8, 2019, in connection with (and immediately prior to) the consummation of the Issuer's initial business combination, Steven Hochberg transferred to AdaptHealth and certain of its equityholders and employees shares of the Issuer's common stock for no consideration.

6. Steven Hochberg, a partner in Deerfield Management Company, served on the board of directors of the Issuer until the expiration of his term as a director immediately following the completion of the AdaptHealth Transaction. The common stock owned by Steven Hochberg and reported herein is held for the benefit, and at the direction, of Deerfield Management.

7. The Private Placement Warrants are substantially similar to the Public Warrants (see Footnote 9), except that, if held by the original holders or their permitted assigns, they (i) may be exercised on a cashless basis, (ii) are not subject to redemption and (iii) subject to certain limited exceptions, are subject to transfer restrictions until 30 days after the completion of the AdaptHealth Transaction. If the Private Placement Warrants are held by holders other than the initial purchaser or its permitted transferees, the Private Placement Warrants will be redeemable by the Issuer and exercisable by the holders on the same basis as the Public Warrants. The Private Placement Warrants expire five years after the completion of the AdaptHealth Transaction or earlier upon redemption or liquidation.

8. The Public Warrants may be exercised only during the period commencing on the date that is thirty days after the AdaptHealth Transaction, provided that the Issuer has an effective registration statement covering the shares of Common Stock issuable upon exercise of the Public Warrants and a current prospectus relating to them is available (or the Issuer permits holders to exercise their warrants on a cashless basis under the circumstances specified in the warrant agreement governing the Public Warrants). The Public Warrants are subject to redemption upon the terms provided in the warrant agreement. The warrants expire five years after the completion of the AdaptHealth Transaction or earlier upon redemption or liquidation.

Remarks:

Steven Hochberg, a partner in Deerfield Management Company, served as a director of the Issuer until his resignation from the Issuer's board of directors immediately following the consummation of the Issuer's initial business combination. Following the transactions reported herein, the Issuer's common stock was reclassified as "Class A Common Stock." Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 3 with regard to Proteon Therapeutics, Inc. filed with the Securities and Exchange Commission on August 4, 2017 by Deerfield Special Situations Fund, L.P., Deerfield Partners, L.P., Deerfield International Master Fund, L.P., Deerfield Private Design Fund III, L.P., Deerfield Private Design Fund IV, L.P., Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Management Company, L.P., and James E. Flynn.

	/s/ Jonathan Isler, Attorney-in-Fact	11/13/2019
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.